These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 31738426

  • 21. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y, Kawano M, Iwasaki T, Itonaga I, Tsumura H, Kaku N, Tanaka K.
    Medicine (Baltimore); 2023 Dec 08; 102(49):e36232. PubMed ID: 38065851
    [Abstract] [Full Text] [Related]

  • 22. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM.
    Cancer Discov; 2017 Sep 08; 7(9):963-972. PubMed ID: 28578312
    [Abstract] [Full Text] [Related]

  • 23. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.
    Kheder ES, Hong DS.
    Clin Cancer Res; 2018 Dec 01; 24(23):5807-5814. PubMed ID: 29986850
    [Abstract] [Full Text] [Related]

  • 24. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ, Jaworski C, Tung D, Wängler C, Wängler B, Schirrmacher R.
    Expert Opin Ther Pat; 2020 May 01; 30(5):325-339. PubMed ID: 32129124
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, López-Ríos F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J.
    BMC Cancer; 2022 Jun 07; 22(1):625. PubMed ID: 35672677
    [Abstract] [Full Text] [Related]

  • 31. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K, Pellat A, Cohen R, Svrcek M, Penault-Llorca F, André T.
    Bull Cancer; 2020 Apr 07; 107(4):447-457. PubMed ID: 32067719
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
    Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME.
    Eur J Endocrinol; 2022 Apr 29; 186(6):631-643. PubMed ID: 35333737
    [Abstract] [Full Text] [Related]

  • 34. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R, Depetris I, Satolli MA.
    Expert Opin Pharmacother; 2021 Apr 29; 22(6):677-684. PubMed ID: 33576301
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights.
    Mahajan AT, Shivani, Datusalia AK, Coluccini C, Coghi P, Chaudhary S.
    Molecules; 2024 Jul 29; 29(15):. PubMed ID: 39124968
    [Abstract] [Full Text] [Related]

  • 40. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
    Murray BW, Rogers E, Zhai D, Deng W, Chen X, Sprengeler PA, Zhang X, Graber A, Reich SH, Stopatschinskaja S, Solomon B, Besse B, Drilon A.
    Mol Cancer Ther; 2021 Dec 29; 20(12):2446-2456. PubMed ID: 34625502
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.